Shots:
- Novartis AG has signed an agreement with ChrysCapital to divest its 70.68% stake in Novartis India Limited (NIL), following a strategic review initiated in Feb 2024
- The transaction, subject to customary closing conditions, is expected to close in Q3’26; the Board of NIL was formally notified post-signing
- Post-divestment, Novartis will further its transition into a pure-play innovative medicines company, aligning its India footprint with its global strategy for sustainable long-term growth
Ref: Novartis | Image: Novartis | Press Release
Related News: Unnatural Products Signs ~$1.8B Licensing Deal with Novartis to Develop Macrocyclic Peptide Therapeutics
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
